Aldosterone receptor antagonists for heart failure: current status, future indications.

Abstract

Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)--in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.

• Authors: Bertram Pitt, Sanjay Rajagopalan
• Journal: Cleveland Clinic journal of medicine (Cleve Clin J Med) Vol. 73 Issue 3 Pg. 257-60, 264-8 (Mar 2006) ISSN: 0891-1150 [Print] United States
• PMID: 16548448 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Mineralocorticoid Receptor Antagonists
• Spironolactone
• Eplerenone

Topics

• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Eplerenone
• Forecasting
• Heart Failure (drug therapy)
• Humans
• Mineralocorticoid Receptor Antagonists (therapeutic use)
• Practice Guidelines as Topic
• Randomized Controlled Trials as Topic
• Risk Factors
• Spironolactone (analogs & derivatives, therapeutic use)